When was NeuroKaire founded?

NeuroKaire was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is NeuroKaire located?

NeuroKaire is headquartered in Kearny, United States.

Who is the current CEO of NeuroKaire?

Talia Cohen Solal of NeuroKaire. They have also founded 1 company.

How many employees does NeuroKaire have?

As of Sep 30, 2026, the latest employee count at NeuroKaire is 43.

Is NeuroKaire a funded company?

NeuroKaire is a funded company, having raised a total of $20M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2018.

When was the latest funding round of NeuroKaire?

NeuroKaire's latest funding was a $***** Series A round on Dec 17, 2024, with participation from 3 investors. Its primary sector is Healthcare IT. In United States, the Healthcare IT sector has seen $6.53B in funding in 2026 to date.

Where does NeuroKaire rank among its competitors?

NeuroKaire ranks 2nd amongst 26 active competitors, of which 6 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Inocras, which secured $31M in Aug, 2026.

Who are the top competitors of NeuroKaire?

NeuroKaire's top competitors include Sophia Genetics, Karius and Inocras. Among them, Inocras secured the most recent funding round in August, 2026.

NeuroKaire - 2026 Company Profile, Team, Funding & Competitors

NeuroKaire is a series A company based in Kearny (United States), founded in 2017 by Talia Cohen Solal. It operates as a Platform offering personalized treatment for psychiatric and neurological conditions. NeuroKaire has raised $20M in funding from GreyBird Ventures. The company has 26 active competitors, including 6 funded and 1 that has exited. Its top competitors include companies like Sophia Genetics, Karius and Inocras.

Company Details

Platform offering personalized treatment for psychiatric and neurological conditions. It provides solutions for psychiatric and neurological conditions, leveraging stem cell technology, RNA expression, neurobiology, and AI to enable precision medicine in CNS disorders. The platform utilizes a blood test and questionnaire to predict optimal medication for patients with depression, revolutionizing mental health care.

Website: www.neurokaire.com/
Social
Email ID: *****@neurokaire.com, *****@neurokaire.com, *****@neurokaire.com

Key Metrics

Founded Year

2017

Location

Kearny, United States

Stage

Series A

Total Funding

$20M in 6 rounds

Latest Funding Round

Series A, Dec 17, 2024, $*****

Investors

GreyBird Ventures & 7 more

Ranked

2^nd among 26 active competitors

Employee Count

43 as on Sep 30, 2026

Similar Companies

Sophia Genetics & 25 more

View NeuroKaire's full profile

NeuroKaire has raised a total funding of $20M over 6 rounds. Its first funding round was on 2018. Its latest funding round was a Series A round on Dec 17, 2024 for $*****. 3 investors participated in its latest round. NeuroKaire has 6 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of NeuroKaire:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 17, 2024	3148435	Series A	8544146	1755129	5405865	4608606
Jul 26, 2022	3413128	Series A	5314606	7401330	9905815	8001783
Jul 26, 2022	3234824	Grant (prize money)	5833585	5684377	5385639	Europa

Access funding benchmarks and valuations. Sign up today!

View details of NeuroKaire's funding rounds and investors

The founders of NeuroKaire is Talia Cohen Solal. Talia Cohen Solal is the CEO of NeuroKaire.

Here are the details of NeuroKaire's key team members:

Talia Cohen Solal: Co-Founder & CEO of NeuroKaire.
Contact Info: 1 email address

View details of NeuroKaire's Founder profiles and Board Members

NeuroKaire's employee count trend

NeuroKaire has 43 employees as of Sep 26. Here is NeuroKaire's employee count trend over the years:

Uncover NeuroKaire's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeuroKaire include Sophia Genetics, Karius and Inocras. Here is the list of Top 10 competitors of NeuroKaire, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sophia Genetics 2011, Rolle (Switzerland), Public	Provider of artificial intelligence software for analyzing complex medical data	$249M	Generation Investment Management, Endeavour Vision ... & 25 others	62/100
2nd	NeuroKaire 2017, Kearny (United States), Series A	Platform offering personalized treatment for psychiatric and neurological conditions	$20M	MassChallenge, Jumpspeed Ventures & 6 others	61/100
3rd	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	60/100
4th	Inocras 2020, San Diego (United States), Series B	AI-driven platform provides whole genome insights for cancer and rare diseases	$100M	Samsung Venture Investment, Dunamu & Partners ... & 19 others	58/100
5th	Elypta 2017, Stockholm (Sweden), Series A	Provider of liquid biopsy-based molecular diagnostics for cancer detection	$27.9M	Industrifonden, Bonnier Capital & 12 others	46/100
6th	Emedgene 2015, Tel Aviv (Israel), Series A	Knowledge management platform to support genetic tests' decision	$6M	OTV, Microsoft & 7 others	44/100
7th	Qnomx 2024, Basel (Switzerland), Seed	Provider of AI-powered genomic data interpretation platform	$1.93M	better ventures, Springboard Health Angels ... & 5 others	39/100
8th	Artificial Intelligence Expert 2019, Cluj napoca (Romania), Funding Raised	Provider of AI-based oncology test	-	EIC Fund, Europa	33/100
9th	Candida.app 2024, Helsinki (Finland), Unfunded	Provider of a web-based application that provides tools for analyzing Candida auris genomes	-	-	30/100
10th	AIR Genomics 2024, Carbajosa De La Sagrada (Spain), Unfunded	AI based solutions for automating the workflow of gene analyses and assisting in diagnostic procedures	-	-	30/100